Skip to main content
Top
Published in: Clinical and Molecular Allergy 1/2016

Open Access 01-12-2016 | Case Report

Mastocytosis and systemic sclerosis: a clinical association

Authors: Gianluca Bagnato, William Neal Roberts, Davide Sciortino, Donatella Sangari, Santa Cirmi, Roneka L. Ravenell, Michele Navarra, Gianfilippo Bagnato, Sebastiano Gangemi

Published in: Clinical and Molecular Allergy | Issue 1/2016

Login to get access

Abstract

Background

Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular alterations and autoimmune activation leading to widespread organ fibrosis. At the early stage of disease when organ involvement and extent of disease are emerging, mast cells may have some role, as implied by both symptoms and histologic evidence.

Case presentation

A female patient diagnosed with cutaneous mastocytosis experienced the onset of systemic sclerosis after 15 years followed by the switch of mastocytosis to the systemic phenotype. A literature review on the evidences related to mast-cells activation in systemic sclerosis is presented below.

Conclusions

For clinicians, more attention must be paid to the potential association between systemic sclerosis and cancer. This case suggests that a proliferative disease in the mast cell compartment—though representing a rare association—may not be completely unexpected in SSc and perhaps excess mast cell activity can serve a pathogenic role in promoting fibrotic disease.
Literature
1.
2.
go back to reference Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63.CrossRefPubMedPubMedCentral Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63.CrossRefPubMedPubMedCentral
3.
go back to reference Mayes MD. The scleroderma book: a guide for patients and families. New York: Oxford University Press; 1999. Mayes MD. The scleroderma book: a guide for patients and families. New York: Oxford University Press; 1999.
4.
6.
go back to reference Razykov I, Thombs BD, Hudson M, et al. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Care Res. 2009;61:1765–70.CrossRef Razykov I, Thombs BD, Hudson M, et al. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Care Res. 2009;61:1765–70.CrossRef
7.
go back to reference Hebbar M, Gillot JM, Hachulla E, Lassalle P, Hatron PY, Devulder B, Janin A. Early expression of E-selectin, tumor necrosis factor alpha, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum. 1996;39(7):1161–5.CrossRefPubMed Hebbar M, Gillot JM, Hachulla E, Lassalle P, Hatron PY, Devulder B, Janin A. Early expression of E-selectin, tumor necrosis factor alpha, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum. 1996;39(7):1161–5.CrossRefPubMed
8.
go back to reference Hügle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2011;63(3):795–9.CrossRefPubMed Hügle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2011;63(3):795–9.CrossRefPubMed
9.
go back to reference Irani AM, Gruber BL, Kaufman LD, Kahaleh MB, Schwartz LB. Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation. Arthritis Rheum. 1992;35(8):933–9.CrossRefPubMed Irani AM, Gruber BL, Kaufman LD, Kahaleh MB, Schwartz LB. Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation. Arthritis Rheum. 1992;35(8):933–9.CrossRefPubMed
10.
go back to reference Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 1998;138(3):399–406.CrossRefPubMed Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 1998;138(3):399–406.CrossRefPubMed
11.
go back to reference Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913–21.CrossRefPubMed Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913–21.CrossRefPubMed
12.
go back to reference Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol. 2010;163(4):800–6.CrossRefPubMed Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol. 2010;163(4):800–6.CrossRefPubMed
13.
go back to reference Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC, Fang YF, Chiou MJ, See LC. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol. 2012;41(1):44–9.CrossRefPubMed Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC, Fang YF, Chiou MJ, See LC. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol. 2012;41(1):44–9.CrossRefPubMed
14.
go back to reference Frigui M, Dupin N, Carlotti A, Bussone G, Pestre V, Charles P, Crabol Y, Bérezné A, Guillevin L, Mouthon L. Telangiectasic mastocytosis with systemic sclerosis. Presse Med. 2013;42(5):902–4.CrossRefPubMed Frigui M, Dupin N, Carlotti A, Bussone G, Pestre V, Charles P, Crabol Y, Bérezné A, Guillevin L, Mouthon L. Telangiectasic mastocytosis with systemic sclerosis. Presse Med. 2013;42(5):902–4.CrossRefPubMed
15.
go back to reference Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24(135):102–14.CrossRefPubMed Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24(135):102–14.CrossRefPubMed
16.
go back to reference Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Saito K, Tanaka Y. Involvement of mast cells in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(2):81–6.CrossRefPubMed Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Saito K, Tanaka Y. Involvement of mast cells in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(2):81–6.CrossRefPubMed
17.
go back to reference Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, Sonomoto K, Saito K, Tanaka Y. Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol. 2013;23(6):1151–7.CrossRefPubMed Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, Sonomoto K, Saito K, Tanaka Y. Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol. 2013;23(6):1151–7.CrossRefPubMed
18.
go back to reference Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 1998;138(3):399–406.CrossRefPubMed Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 1998;138(3):399–406.CrossRefPubMed
19.
go back to reference Hügle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2011;63(3):795–9.CrossRefPubMed Hügle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2011;63(3):795–9.CrossRefPubMed
20.
go back to reference Hügle T. Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 2014;3(144):w13999. Hügle T. Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 2014;3(144):w13999.
21.
go back to reference Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33(11):1481–4.CrossRefPubMedPubMedCentral Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33(11):1481–4.CrossRefPubMedPubMedCentral
22.
go back to reference Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, et al. Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56(1):323–33.CrossRefPubMed Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, et al. Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56(1):323–33.CrossRefPubMed
23.
go back to reference Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–24.CrossRefPubMed Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–24.CrossRefPubMed
24.
go back to reference Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W, Corvetta A, Gabrielli A, Moroncini G. Imatinib in Scleroderma Italian Study Group. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144. doi:10.1186/ar4606.CrossRefPubMedPubMedCentral Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W, Corvetta A, Gabrielli A, Moroncini G. Imatinib in Scleroderma Italian Study Group. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144. doi:10.​1186/​ar4606.CrossRefPubMedPubMedCentral
Metadata
Title
Mastocytosis and systemic sclerosis: a clinical association
Authors
Gianluca Bagnato
William Neal Roberts
Davide Sciortino
Donatella Sangari
Santa Cirmi
Roneka L. Ravenell
Michele Navarra
Gianfilippo Bagnato
Sebastiano Gangemi
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Clinical and Molecular Allergy / Issue 1/2016
Electronic ISSN: 1476-7961
DOI
https://doi.org/10.1186/s12948-016-0050-3

Other articles of this Issue 1/2016

Clinical and Molecular Allergy 1/2016 Go to the issue